Eisai Drug That Failed For Sepsis Could Be New Way To Treat Evolving Flu
This article was originally published in PharmAsia News
An Eisai drug that failed testing for treating another disease may be able to provide a new way of treating influenza, including the new viruses, by acting on the patient instead of the virus.
You may also be interested in...
Partnering with AstraZeneca, the Oxford team has opened up a clear lead in the race to enrol thousands of patients for late-stage safety and efficacy trials – but cannot make guarantees of when results might be ready.
With a late-stage compound on its hands, MGB is currently in discussions with several biotech and pharma companies and also with venture capitalists to continue late-stage development of a novel antibiotic which could transform treatment of Clostridium difficile.
AZ and the EU are at loggerheads over supplies of the COVID-19 vaccine. On top of that, its marketing authorization will present dilemmas.